At-Home Urine Test Can Detect Aggressive Prostate Cancer
By Dennis Thompson HealthDay Reporter
TUESDAY, Feb. 4, 2025 -- It’s tough for a man to know what to do following a diagnosis of prostate cancer.
The treatment is often worse than the risk posed by the cancer itself, causing some men to suffer incontinence and impotence even though their tumor wouldn’t have killed them.
It’s sometimes better -- but unnerving -- to simply live with the cancer and keep it under observation.
Now, a new genetics-driven urine test can help clear up that confusion by helping identify aggressive prostate cancers that are more likely to lead to a man’s early death, a new study says.
What’s more, the test sample can be taken at home and sent in for analysis, researchers say.
The test, called MyProstateScore 2.0 (MPS2), looks at 18 genes linked to aggressive prostate cancers.
The urine test detected 94% of aggressive prostate cancers, a rate more sensitive than that of PSA blood tests, researchers recently reported in The Journal of Urology.
“Its primary benefit is that the test can accurately predict your probability of developing aggressive prostate cancer, putting both the patient and physician at ease,” co-researcher Dr. Ganesh Palapattu, chair of urology at the University of Michigan, said in a news release.
The current gold-standard test for prostate cancer is the prostate-specific antigen (PSA) test, which looks in blood for a protein released by an inflamed prostate.
However, fewer than 25% of men with an elevated PSA have a type of prostate cancer that needs immediate treatment, according to Lynx Dx, manufacturer of the urine test.
Previous studies had shown that the MyProstateScore 2.0 test could effectively judge the severity of prostate cancer, but those results had occurred after a rectal exam, researchers said.
A rectal exam squishes the prostate, making it more likely that DNA debris from a tumor would wind up in the patient’s urine sample.
The new results show that the urine test could be taken at home and sent in, given that it will be as accurate even without a rectal exam.
In fact, Lynx Dx announced Monday following the study’s publication that they will make MyProstateScore 2.0 available for at-home collection sampling.
The urine test “now empowers patients to collect their samples in the comfort of their homes, a significant step forward in prostate cancer risk assessment and our commitment to patient-centered care,” Dr. Spencer Heaton, chief medical officer at Lynx Dx, said in a news release.
For the study, researchers ran the test using urine from 266 men who had not undergone a rectal exam.
The results also showed that using the test would have avoided up to 53% of unnecessary prostate biopsies, researchers said.
Researchers plan to study the test’s ability to judge low-risk prostate cancers in men.
The test “could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers,” Palapattu said.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-02-05 00:00
Read more
- Higher Intake of Red Meat Linked to Increased Risk for Dementia
- Fitter Folks Have Better Odds Against Cancer
- Seniors Miss Out on Services With Medicare Advantage
- Analyses Suggest No Causal Effect of Smoking Behavior on Chronic Kidney Disease
- FDA Adds Warning Label to RSV Vaccines Abrysvo and Arexvy
- More Abortions Tied to Natural Family Planning or Fertility Awareness Methods
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions